{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:24:52Z","timestamp":1790799892021,"version":"4.1.0"},"reference-count":72,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.15.04322","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:50:40Z","timestamp":1766998240000},"source":"Crossref","is-referenced-by-count":11,"title":["Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review"],"prefix":"10.7189","volume":"15","author":[{"given":"Thom WL","family":"de Milliano","sequence":"first","affiliation":[{"name":"Santen SA, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Shi-van Wielink","sequence":"additional","affiliation":[{"name":"Santen Pharmaceutical SA, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Ernst","sequence":"additional","affiliation":[{"name":"Santen Pharmaceutical GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarjuna","family":"Mulkalapalli","sequence":"additional","affiliation":[{"name":"IQVIA, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravali","family":"Pagidigummula","sequence":"additional","affiliation":[{"name":"IQVIA, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lymperopoulou","sequence":"additional","affiliation":[{"name":"IQVIA, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"key-10.7189\/jogh.15.04322-202512290928-R1","first-page":"116","article-title":"Childhood myopia: epidemiology, risk factors, and prevention.","volume":"112","author":"Recko","year":"2015","journal-title":"Mo Med"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.62.5.3","article-title":"IMI risk factors for myopia.","volume":"62","author":"Morgan","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R3","unstructured":"Yoo SH. Myopia (nearsightedness) in children & teens. American Academy of Pediatrics; 2023. Available: https:\/\/www.healthychildren.org\/English\/health-issues\/conditions\/eyes\/Pages\/Myopia-Nearsightedness.aspx. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R4","unstructured":"Cooper Y. With childhood myopia rates on the rise, the American Optometric Association Highlights the Importance of Ealy Intervention through Annual Eye Exams. 2019. Available: https:\/\/www.aoa.org\/about-the-aoa\/press-room\/press-releases\/myopia-rates-on-the-rise. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R5","unstructured":"American Optometric Association. Optometric clinical practice guideline. Care of the Patient with Myopia. St. Louis, Missouri, USA: American Optometric Association; 2006. Available: https:\/\/www.aoa.org\/AOA\/Documents\/Practice%20Management\/Clinical%20Guidelines\/Consensus-based%20guidelines\/Care%20of%20Patient%20with%20Myopia.pdf. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/1120672121998960","article-title":"Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.","volume":"31","author":"N\u00e9meth","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R7","unstructured":"Shah VA, Lauer AK, Sundy M, Khadamy J, Cui RZ, Hsu J, et al. Pathologic Myopia (Myopic Degeneration) 2024. Available: https:\/\/eyewiki.org\/Pathologic_Myopia_(Myopic_Degeneration). Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R8","unstructured":"American Optometric Association. Clinical Report: Myopia Management. Developed by the Evidence-based Optometry Committee. St. Louis, Missouri, USA: American Optometric Association; 2021. Available: https:\/\/global.vtivision.com\/wp-content\/uploads\/sites\/4\/2023\/04\/Evidenced-Based-Optometry-Myopia-Clinical-Report.pdf. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R9","doi-asserted-by":"crossref","unstructured":"Jeganathan V, Saw SM, Wong TY. Book Chapter-Ocular morbidity of pathological myopia. In: Beuerman RW, Saw SM, Tan DTH, Wong TY, ed. Myopia: Animal Models to Clinical Trials. World Scientific, Singapore Eye Research Institute: Singapore, 2010. Available: https:\/\/www.researchgate.net\/publication\/304818559_Myopia_Animal_Models_to_Clinical_Trials. Accessed: 8 December 2025.","DOI":"10.1142\/9789812832986_0006"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R10","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.ophtha.2012.04.020","article-title":"The association between time spent outdoors and myopia in children and adolescents: a systematic review and meta-analysis.","volume":"119","author":"Sherwin","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.5.5","article-title":"IMI pathologic myopia.","volume":"62","author":"Ohno-Matsui","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R13","first-page":"CD014758","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis.","volume":"2","author":"Lawrenson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/bjo-2024-325427","article-title":"Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis.","volume":"109","author":"Liang","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R15","doi-asserted-by":"publisher","first-page":"e82763","DOI":"10.1371\/journal.pone.0082763","article-title":"Refractive error, visual acuity and causes of vision loss in children in Shandong, China. The Shandong Children Eye Study.","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09286586.2014.928824","article-title":"Differences in prevalence of refractive errors in young Asian males in Singapore between 1996\u20131997 and 2009\u20132010.","volume":"21","author":"Koh","year":"2014","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R17","doi-asserted-by":"publisher","first-page":"M184","DOI":"10.1167\/iovs.18-25977","article-title":"IMI\u2013clinical management guidelines report.","volume":"60","author":"Gifford","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis.","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis.","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R20","doi-asserted-by":"publisher","first-page":"1093836","DOI":"10.3389\/fpubh.2023.1093836","article-title":"Cost-effectiveness analysis of myopia management: A systematic review.","volume":"11","author":"Agyekum","year":"2023","journal-title":"Front Public Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R21","doi-asserted-by":"publisher","first-page":"750132","DOI":"10.3389\/fmed.2021.750132","article-title":"Cost-effectiveness of Conbercept vs. Ranibizumab for age-related macular degeneration, diabetic macular edema, and pathological myopia: population-based cohort study and Markov model.","volume":"8","author":"Cui","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI impact of myopia.","volume":"62","author":"Sankaridurg","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control.","volume":"33","author":"Wu","year":"2019","journal-title":"Eye.(Lond)"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R24","first-page":"5466","article-title":"Predicting Costs and Disability from the Myopia Epidemic\u2013A Worldwide Economic and Social Model.","volume":"60","author":"Holy","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/bjophthalmol-2018-313798","article-title":"Current and emerging pharmaceutical interventions for myopia.","volume":"103","author":"Vutipongsatorn","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R26","doi-asserted-by":"publisher","first-page":"e2340986","DOI":"10.1001\/jamanetworkopen.2023.40986","article-title":"Cost-effectiveness analysis of myopia progression interventions in children.","volume":"6","author":"Agyekum","year":"2023","journal-title":"JAMA Network Open"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R27","unstructured":"Inflation rate, average consumer prices Annual percent change: International Monetary Fund; 2025. Available: https:\/\/www.imf.org\/external\/datamapper\/PCPIPCH@WEO\/OEMDC\/ADVEC\/WEOWORLD. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R28","unstructured":"Official exchange rate (LCU per US$, period average): World Bank Group; 2024. Available: https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R30","unstructured":"PMG24-Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template. NICE. 2024.Available: https:\/\/www.nice.org.uk\/process\/pmg24. Accessed: 15 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R31","first-page":"821","article-title":"Cost-Effectiveness Analysis of Atropine for Treating Myopia Progression in Children.","volume":"64","author":"Agyekum","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R32","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2147\/OPTH.S362342","article-title":"Photorefraction screening plus atropine treatment for myopia is cost-effective: a proof-of-concept Markov analysis.","volume":"16","author":"Hong","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R33","first-page":"34","article-title":"Cost-effectiveness of myopia control by use of defocus incorporated multiple segments lenses: abridged secondary publication.","volume":"29","author":"Lian","year":"2023","journal-title":"Hong Kong Med J"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R34","doi-asserted-by":"publisher","first-page":"100837","DOI":"10.1016\/j.lanwpc.2023.100837","article-title":"Implementing a digital comprehensive myopia prevention and control strategy for children and adolescents in China: a cost-effectiveness analysis.","volume":"38","author":"Li","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/eye.2008.225","article-title":"Direct costs of myopia in Singapore.","volume":"23","author":"Lim","year":"2009","journal-title":"Eye (Lond)"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3928\/1081597X-20211007-01","article-title":"Comparison of the Cost-Effectiveness of SMILE, FS-LASIK, and PRK for Myopia in a Private Eye Center in Spain.","volume":"38","author":"Balgos","year":"2022","journal-title":"J Refract Surg"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R37","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2214-109X(22)00554-X","article-title":"Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a cost-effectiveness analysis.","volume":"11","author":"Liu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R38","doi-asserted-by":"publisher","first-page":"A503","DOI":"10.1016\/j.jval.2013.08.1149","article-title":"The Budget Impact of Introducing Ranibizumab in England and Wales for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.","volume":"16","author":"Malcolm","year":"2013","journal-title":"Value Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R39","doi-asserted-by":"publisher","first-page":"A505","DOI":"10.1016\/j.jval.2013.08.1162","article-title":"Cost-Effectiveness of Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia in the United Kingdom.","volume":"16","author":"Leteneux","year":"2013","journal-title":"Value Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R40","first-page":"S601","article-title":"PDG26 Cost-effectiveness of ranibizumab versus verteporfin photodynamic therapy in the treatment of choroidal neovasuclarization secondary to pathological myopia: from chinese societal perspective.","volume":"22","author":"Liu","year":"2019","journal-title":"Value Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R41","doi-asserted-by":"publisher","first-page":"S886","DOI":"10.1016\/j.jval.2019.09.2566","article-title":"Cost-effectiveness analysis of conbercept versus ranibizumab for the treatment of myopic choroidal neovascularization (CNV) in China.","volume":"22","author":"Zhang","year":"2019","journal-title":"ISPOR Europe"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10384-016-0496-3","article-title":"Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.","volume":"61","author":"Yang","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R43","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1167\/iovs.13-12795","article-title":"The economic cost of myopia in adults aged over 40 years in Singapore.","volume":"54","author":"Zheng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.oftal.2016.01.013","article-title":"Cost of myopic patients with and without myopic choroidal neovascularisation.","volume":"91","author":"Ruiz-Moreno","year":"2016","journal-title":"Arch Soc Esp Oftalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R45","doi-asserted-by":"publisher","first-page":"A284","DOI":"10.1016\/j.jval.2014.03.1657","article-title":"Canadian Burden Of Choroidal Neovascularization Secondary To Pathologic Myopia: Final Results.","volume":"17","author":"Zaour","year":"2014","journal-title":"Value Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R46","first-page":"2404","article-title":"Estimated global productivity loss from myopia.","volume":"58","author":"Naidoo","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R47","doi-asserted-by":"publisher","first-page":"11003","DOI":"10.7189\/jogh.12.11003","article-title":"Healthcare utilization and economic burden of myopia in urban China: a nationwide cost-of-illness study.","volume":"12","author":"Ma","year":"2022","journal-title":"J Glob Health"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R48","article-title":"P29-Factors affecting the lifetime cost of myopia and the impact of anti myopia treatments [abstract].","author":"Fricke","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R49","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcz076","article-title":"We can\u2019t afford to turn a blind eye to myopia.","volume":"116","author":"Bourke","year":"2023","journal-title":"QJM"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/OPX.0000000000000796","article-title":"Global Vision Impairment and Blindness Due to Uncorrected Refractive Error, 1990-2010.","volume":"93","author":"Naidoo","year":"2016","journal-title":"Optom Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI Impact of Myopia.","volume":"62","author":"Sankaridurg","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R52","unstructured":"World Health Organization. World Report on Vision. Geneva, Switzerland: World Health Organisation; 2019. Available: https:\/\/www.who.int\/Publications\/i\/Item\/9789241516570. Accessed: 25 August 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ophtha.2018.10.029","article-title":"Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling.","volume":"126","author":"Naidoo","year":"2019","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R54","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/09286586.2013.842596","article-title":"Design, methodology and baseline data of a school-based cohort study in Central China: the Anyang Childhood Eye Study.","volume":"20","author":"Li","year":"2013","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI prevention of myopia and its progression.","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ophtha.2022.10.030","article-title":"Pediatric eye evaluations preferred practice pattern.","volume":"130","author":"Hutchinson","year":"2023","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R57","unstructured":"Harewood J, Contreras M, Huang K, Leach S, Wang J. Access to Myopia Care \u2013 A Scoping Review. 2024. Available: https:\/\/nap.nationalacademies.org\/resource\/27734\/Harewood_et_al_Access_to_Myopia_Care_-_A_Scoping_Review.pdf. Accessed: 16 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.healthpol.2008.06.003","article-title":"Cost-effectiveness of screening and correcting refractive errors in school children in Africa, Asia, America and Europe.","volume":"89","author":"Baltussen","year":"2009","journal-title":"Health Policy"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R59","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1111\/aos.13954","article-title":"The cost-effectiveness of alternative vision screening models among preschool children in rural China.","volume":"97","author":"Wang","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R60","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/09286580903312277","article-title":"Screening for refractive error and fitting with spectacles in rural and urban India: cost-effectiveness.","volume":"16","author":"Frick","year":"2009","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/09286586.2020.1791348","article-title":"Relationship between geography and refractive error from the UCLA Preschool Vision Program.","volume":"28","author":"Tam","year":"2021","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R62","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/OPX.0000000000000980","article-title":"What public policies should be developed to deal with the epidemic of myopia?","volume":"93","author":"Morgan","year":"2016","journal-title":"Optom Vis Sci"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R63","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.1289\/ehp.122-A12","article-title":"Myopia: the evidence for environmental factors.","volume":"122","author":"Lougheed","year":"2014","journal-title":"Environ Health Perspect"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R64","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R65","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report.","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R66","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans.","volume":"30","author":"Polling","year":"2016","journal-title":"Eye (Lond)"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R67","unstructured":"World Health Organization. Western Pacific Regional strategy for health systems based on the values of primary health care. Geneva, Switzerland: World Health Organization; 2010. Available: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/168beb13-f24f-42e2-b37d-566e0d936cfa\/content. Accessed: 8 December 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R68","doi-asserted-by":"publisher","first-page":"718724","DOI":"10.3389\/fmed.2021.718724","article-title":"Cost of myopia correction: a systematic review.","volume":"8","author":"Foo","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R69","doi-asserted-by":"publisher","first-page":"d4793","DOI":"10.1136\/bmj.d4793","article-title":"Correcting refractive error in low income countries.","volume":"343","author":"Keay","year":"2011","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R70","unstructured":"World Health Organization. Promising progress on eye health in African region, but challenges remain. 2024. Available: https:\/\/www.afro.who.int\/news\/promising-progress-eye-health-african-region-challenges-remain. Accessed: 25 August 2025."},{"key":"key-10.7189\/jogh.15.04322-202512290928-R71","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41433-024-03032-1","article-title":"Priorities in school eye health in low and middle-income countries a scoping review.","volume":"38","author":"Harvey","year":"2024","journal-title":"Eye (Lond)"},{"key":"key-10.7189\/jogh.15.04322-202512290928-R72","unstructured":"Fletcher ER. Upwards of 800 Million People with Vision Impairments Lack Access to Eyeglasses. 2024. Available: https:\/\/healthpolicy-watch.news\/upwards-of-500-million-people-with-vision-impairments-lack-access-to-eyeglasses\/. Accessed: 24 February 2025."}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"https:\/\/jogh.org\/2025\/jogh-15-04322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:50:44Z","timestamp":1766998244000},"score":1,"resource":{"primary":{"URL":"https:\/\/jogh.org\/2025\/jogh-15-04322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":72,"URL":"https:\/\/doi.org\/10.7189\/jogh.15.04322","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"article-number":"04322"}}